Bio Solution

Bio Solution is an advanced biopharmaceutical company focused on developing and commercializing cell therapies, operating four business segments: skin cell therapy, cartilage cell therapy, human tissue models, and bio-convergence materials.

The skin cell therapy segment is anchored by 'Keraheal,' an autologous keratinocyte therapy for burn treatment, and its allogeneic counterpart 'Keraheal-Allo,' both of which have obtained advanced biopharmaceutical product approvals.

The cartilage cell therapy segment's flagship product is 'CartiLife,' an autologous cartilage cell therapy for knee cartilage defects and osteoarthritis, produced by culturing cells harvested from a patient's own rib cartilage before implantation.

The human tissue model segment offers animal-alternative testing and CRO services through products such as the skin model 'KeraSkin,' corneal model 'MCTT HCE,' respiratory model 'SoluAirway,' and oral mucosa model 'SoluOral,' and at CPHI Korea in August 2026 the company ran a joint booth with Merck Life Science, the life science division of Germany's Merck, on the theme of animal-alternative testing solutions.

The company became the largest shareholder of affiliate Helixmith after acquiring its stake in late 2023, and as of the end of the first half of this year it held 8,403,471 shares of Helixmith, a 18.25% stake.

In terms of competitive positioning, GC Cell's 'Cartistem,' Mediphostem's allogeneic stem cell therapies, and Kolon TissueGene's gene therapy 'Invossa' occupy competing or adjacent positions in the cartilage and joint regeneration therapy market.

The domestic market for cartilage defect and osteoarthritis treatments is estimated at around KRW 400 billion, with roughly 4 million patients, but CartiLife's actual target market is estimated at around KRW 100 billion, suggesting the domestic market alone offers limited growth potential.

As a result, the company is pursuing overseas expansion into the US, China, and Japan in parallel, while developing follow-on pipeline candidates such as the allogeneic 'CartiLoid' and injectable 'SpheroCure' to address the limitations of the autologous approach.

Bio Solution's consolidated revenue rose for four consecutive years, from KRW 10.1 billion in 2022 to KRW 12.5 billion in 2023, KRW 12.9 billion in 2024, and KRW 15.2 billion in 2025.

However, operating losses persisted over the same four years at -KRW 5.29 billion, -KRW 5.03 billion, -KRW 5.07 billion, and -KRW 4.34 billion respectively, with the 2025 operating margin improving to -28.6% but still deeply negative.

The net profit trajectory was more dramatic: net losses of -KRW 8.09 billion in 2022 and -KRW 1.25 billion in 2023 widened sharply to -KRW 11.93 billion in 2024 before swinging to a net profit of +KRW 0.27 billion in 2025.

Behind this turnaround was improved performance and value recovery at affiliate Helixmith, of which Bio Solution is the largest shareholder; as confirmed in reporting, as improvement in Helixmith's performance and recovery of corporate value became evident, about KRW 4.8 billion of previously recognized impairment on the associate investment asset was reversed, which was the key factor behind the swing to consolidated net profit.

On a quarterly basis, Q3 2025 revenue was KRW 4.51 billion with an operating loss of -KRW 1.10 billion and a net loss of -KRW 1.86 billion; in Q4 2025, revenue was KRW 4.42 billion, the operating loss narrowed to -KRW 0.48 billion, and net profit surged to +KRW 5.50 billion, a result also largely attributable to non-operating gains related to Helixmith.

Moving into 2026, Q1 revenue fell to KRW 3.76 billion with the operating loss widening again to -KRW 1.30 billion and a net loss of -KRW 2.04 billion, while Q2 revenue rebounded to KRW 4.70 billion but the operating loss of -KRW 0.48 billion and net loss of -KRW 0.74 billion continued.

Over the trailing four quarters (Q3 2025 through Q2 2026), cumulative owner net profit stood at a modest KRW 0.87 billion, suggesting it is still premature to conclude that the annual profit swing is being consistently reproduced each quarter.

In sum, revenue growth is clear, but core profitability improvement remains gradual, and net profit swings are heavily influenced by non-operating items tied to the affiliate.

The global market for osteoarthritis and cartilage regeneration therapies is projected to grow from USD 7.3 billion in 2019 to USD 11 billion by 2025, with the United States representing the largest market by both value and patient population.

Domestically, following CartiLife's transition from conditional to formal product approval, a two-way competitive structure is emerging, as the company itself noted that together with an already-approved stem cell therapy from another domestic company, the two treatments would form the two main pillars of the market.

In China, the government first announced a medical opening policy covering four zones including Hainan through the Ministry of Commerce in November 2024, and CartiLife's use of this framework to bypass the normally decade-plus formal approval process via Hainan's fast-track new-technology policy is viewed as an industrially significant precedent.

Among competitors, Mediphostem has received US Phase 3 approval for its allogeneic mesenchymal stem cell therapy Cartistem, and has already completed Phase 3 trials in Japan, pursuing an independent overseas expansion strategy that differs from Bio Solution's partnership-oriented approach.

On the procedural side, CartiLife also faces convenience limitations due to its two-step procedure structure, underscoring an industry-wide shift toward single-administration allogeneic and injectable therapies.

The human tissue model and animal-alternative testing CRO segment is expected to benefit from expanding regulatory demand to reduce animal testing in cosmetics and pharmaceutical ingredient evaluation, with growing collaboration between global life science majors.

Overall, the industry is in an early commercialization phase for cell and gene therapies (advanced regenerative medicine), where competition to secure early market entry via expedited regulatory pathways such as RMAT designation and Hainan's fast-track policy is intensifying.

The company has outlined a phased expansion plan for CartiLife's China business, stating it plans to start with 1,000 annual procedures in 2027 and scale up to a cumulative 5,000 within three years.

At Boao International Hospital in Hainan, the company is also pursuing an operating system capable of supplying and administering CartiLife to more than 1,000 patients per hospital annually, and plans to expand from Hainan into major inland cities such as Beijing, Shanghai, and Hangzhou, as well as Singapore.

Regarding mainland China market entry, the company stated it plans to accumulate real-world data in the regulatory-relaxed zone for use in NMPA approval and mainland registration, aiming to enter the mainland market within a year at the earliest.

For the US market, the strategy is to pursue Phase 3 jointly with a global partner, given the limitations of going it alone considering approval, manufacturing, and distribution beyond the clinical trial itself, with a company representative explaining, "we are looking for a partner with manufacturing, CMC, GMP, and marketing capabilities in mind for commercialization after Phase 3,